One of the most serious complications of the treatment of severe haemophilia A is the development of alloantibodies against exogenous factor VIII ( FVIII). Inhibitors render factor replacement therapy ineffective, exposing patients to a remarkably high risk of morbidity and mortality. Besides the well-known bypassing agents ( i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in newer haemostatic therapies that are not based on the replacement of the deficient FVIII. This review will focus on the most interesting among these innovative therapies, emicizumab, and will provide an update on its current stage of clinical development.

Emicizumab for the treatment of haemophilia A. a narrative review / Franchini, Massimo; Marano, Giuseppe; Pati, Ilaria; Candura, Fabio; Profili, Samantha; Veropalumbo, Eva; Masiello, Francesca; Catalano, Liviana; Piccinini, Vanessa; Vaglio, Stefania; Pupella, Simonetta; Liumbruno, Giancarlo M. - In: BLOOD TRANSFUSION. - ISSN 1723-2007. - 17:3(2019), pp. 223-228. [10.2450/2019.0026-19]

Emicizumab for the treatment of haemophilia A. a narrative review

Vaglio, Stefania;
2019

Abstract

One of the most serious complications of the treatment of severe haemophilia A is the development of alloantibodies against exogenous factor VIII ( FVIII). Inhibitors render factor replacement therapy ineffective, exposing patients to a remarkably high risk of morbidity and mortality. Besides the well-known bypassing agents ( i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in newer haemostatic therapies that are not based on the replacement of the deficient FVIII. This review will focus on the most interesting among these innovative therapies, emicizumab, and will provide an update on its current stage of clinical development.
2019
emicizumab; haemophilia A; inhibitors; bleeding
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Emicizumab for the treatment of haemophilia A. a narrative review / Franchini, Massimo; Marano, Giuseppe; Pati, Ilaria; Candura, Fabio; Profili, Samantha; Veropalumbo, Eva; Masiello, Francesca; Catalano, Liviana; Piccinini, Vanessa; Vaglio, Stefania; Pupella, Simonetta; Liumbruno, Giancarlo M. - In: BLOOD TRANSFUSION. - ISSN 1723-2007. - 17:3(2019), pp. 223-228. [10.2450/2019.0026-19]
File allegati a questo prodotto
File Dimensione Formato  
Franchini_Emicizumab_2019.pdf

accesso aperto

Note: http://www.bloodtransfusion.it/
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1304876
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 36
social impact